Biotech success, 2005 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech success, 2005

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

From: tom pope	4/6/2005 8:48:00 AM
	Read Replies (2) of 17

does this make the cut? Rituxan Arthritis Trial Meets Endpoint Wednesday April 6, 8:38 am ET Genentech, Biogen and Roche Say Rituxan Rheumatoid Arthritis Trial Meets Primary Endpoint SOUTH SAN FRANCISCO, Calif. (AP) -- Biotech companies Genentech Inc. and Biogen Idec Inc. and Swiss drug maker Roche said Wednesday that a late-stage clinical trial for the therapeutic antibody Rituxan met its primary endpoint in rheumatoid arthritis patients. The companies said that when compared to placebo a greater proportion of rheumatoid arthritis patients taking Rituxan for 24 weeks showed a 20 percent improvement in the number of swollen and tender joints, and a 20 percent improvement in three of five disease-activity measures. The 520-patient study enrolled rheumatoid arthritis sufferers who were intolerant or had not responded to prior treatments for the condition. Both the Rituxan and placebo groups were also given the anti-inflammatory drug methotrexate. The companies plan to present further analysis of the data at an upcoming medical meeting. Rituxan targets B cells, or a type of white blood cell, without targeting stem cells or existing plasma cells. B cells may play multiple roles in the pathophysiology of rheumatoid arthritis, the companies said.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext